ClinicalTrials.gg
RecruitingNCT07225751ASTRAUpdated Sep 1, 2026

A Prospective, Randomized, Single-blind, Controlled, Multi-center Study to Assess the Safety and Performance of MagnetOsTM Compared to Autogenous Bone Graft in Patients Undergoing Hindfoot or Ankle Fusions.

An interventional study of MagnetOs and Autograft in Ankle Arthrodesis or Arthroplasty, Hindfoot Fusion and Ankle Deformity, sponsored by Kuros Biosurgery AG. Recruiting at 7 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Kuros Biosurgery AG · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a phase IV post-marketing study for MagnetOs Putty and MagnetOs Easypack Putty. MagnetOs is a synthetic bone graft extender product that is routinely used by surgeon as treatment for hindfoot and ankle disorders.

In this study, MagnetOs Putty and MagnetOs Easypack Putty will be use according to the latest Instructions For Use, standalone in the foot and ankle.

Read the detailed description

In this study, following a screening period of a maximum of 45 days, approximately 126 patients will receive either MagnetOs Putty/Easypack Putty or autograft in conjunction with rigid hardware (arthrodesis) to treat hindfoot and ankle disorders. They will be randomized (1:1) into one of two treatment groups: standard rigid fixation with MagnetOs Putty/Easypack Putty or local autograft from the calcaneus, distal tibia, or proximal tibia.

They will be followed up at discharge at weeks 2, 6, 12, 24 and 52 post-surgery. The primary endpoint will be analyzed at 24 weeks post-op using CT-scan, and patients will continue follow-up for safety and efficacy for one year post operatively.

In this study, MagnetOs will be applied according to the IFU (Putty) approved in the US, Europe, Middle- East and Australia and Easypack Putty (approved in the US).

The surgical procedures studied in this clinical trial will include rigid hardware fixation and supplemental bone graft/substitute in the following procedures: ankle fusion (tibiotalar), subtalar fusion (talocalcaneal), calcaneocuboid fusion, talonavicular fusion, OR double fusion (any combination of any two of the following: subtalar, talonavicular and calcaneocuboid joints. These procedures will be left to the investigator's discretion.

Radiographs images will be taken at screening, weeks 6, 12, 24 and 52; CT-scans will be taken at weeks 24 and 52 post-op If the patient has a secondary surgical intervention (procedure that adjusts or in any way modifies or removes part of the original implant configuration) at any time after the 6 month visit, the next CT scan will not be necessary. Starting at week 12, all XR images will be weight bearing.

02

Conditions studied

  • Ankle Arthrodesis or Arthroplasty
  • Hindfoot Fusion
  • Ankle Deformity
  • Ankle Disease
  • Hindfoot Arthrodesis
  • Hindfoot Pathologies

Keywords

  • ankle arthrodesis
  • hindfoot fusion
03

In context

Lead sponsor

Kuros Biosurgery AG is the lead sponsor of 12 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is able to read/be read, understand, and provide written and has signed the IRB approved informed consent.
  2. Male or female patient ≥ 18 (considered skeletally mature) up to and including 75 years old
  3. Patients requiring one of the following hindfoot fusion procedures, using surgical technique, necessitating rigid hardware fixation and supplemental bone graft/ substitute: ankle fusion (tibiotalar) subtalar fusion (talocalcaneal), calcaneocuboid fusion, talonavicular fusion, OR double fusion (any combination of any two of the following: subtalar, talonavicular and calcaneocuboid joints).
  4. Hardware parameters - rigid fixation using screws, plates, staples, nails or a combination.

Exclusion criteria

Exclusion:

  1. Expected to need secondary intervention within one year following surgery.
  2. Had prior fusion or attempted fusion of the joints to be fused.
  3. Patient is not ambulatory.
  4. Surgical technique where bone graft is not expected to be used.
  5. Conditions at the surgeon's discretion in which general bone grafting is not advisable.
  6. Radiographic evidence of fractures or pathologies around the fusion that could negatively impact the fusion process (e.g., growth plate fracture around the fusion or bone cysts).
  7. Significant vascular impairment proximal to the graft site.
  8. Acute and/or chronic infections in the operated area (soft tissue infections; bacterial bone diseases; osteomyelitis)
  9. Pre-existing sensory impairment (e.g. diabetes, Charcot). Diabetics patients with greater than 7.0 OR that were not sensitive to the 5.07 monofilament will be excluded.
  10. Metabolic disorders know to adversely affect the skeleton (e.g., renal osteodystrophy or hypercalcemia).
  11. If intraoperative soft tissue coverage is not planned or possible.
  12. Receiving treatment with medication interfering with calcium metabolism (chronic use of and use high dose NSAIDs 800 mg TID for > the first 6 weeks post-op).
  13. Has benign or malignant tumor at the surgical site.
  14. Has history or presence of active (non-invasive skin cancer is allowed).
  15. Has known substance abuse, psychiatric disorder, or a condition which, in the opinion of the investigator, may influence the healing or ability to comply with protocol requirements (e.g. prisoners, physically or mentally compromised, etc.).
  16. Is involved in active litigation relating to his/her foot and ankle condition.
  17. Participation in an study within 30 days prior to surgery for study devices.
  18. Patient with (BMI) > 50.
  19. Patient cannot comply with all post-operative evaluation and visits .
  20. Any pre-existing condition that the surgeon determines could interfere with the patient's ability to perform objective functional measurements.
  21. Women who are or intend to become pregnant within the next 12 months.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
126 participants (estimated)

Study arms

  • Experimental
    MagnetOs

    Interventions * Procedure: Instrumented hindfoot or ankle fusion * Device: MagnetOs Putty or MagnetOs Easypack Putty

    Device: MagnetOs

  • Active comparator
    Autograft

    Interventions * Procedure: Instrumented hindfoot or ankle fusion * Device: Autograft

    Other: Autograft

Interventions

  • DeviceMagnetOs

    MagnetOs will be used at a volume of approximately 1-5 cc's for the TN, CC and ST joints, and up to 10 cc's for the tibiotalar joint.

  • OtherAutograft

    In this study, the comparator is autograft and will be used at a volume of approximately 1-5 cc's for the TN, CC and ST joints, and up to 10 cc's for the tibiotalar joint.

06

What researchers measure

Primary outcomes

  1. Radiographic fusion by CT scan

    The primary endpoint is the incidence of fusion at each side by CT analysis as assessed by the independent radiological expert at 24 weeks post-op

    Time frame: Week 24 post-op

Secondary outcomes

  1. Radiographic fusion by CT scan

    Joint fusion at Week 52 post-surgery assessed by CT-scans determined by an independent radiological expert panel (IREP) in patients undergoing hindfoot or ankle fusions

    Time frame: Week 52

  2. Radiographic Fusion by plain radiographs

    Joint fusion at Week 12, Week 24 and Week 52 post-surgery assessed by plain radiographs determined by an independent radiological expert panel (IREP) in patients undergoing hindfoot or ankle fusions

    Time frame: week 12, week 24, week 52 post-surgery

  3. Functional

    Change in Foot Function Index (FFI) from Screening to Week 2, Week 6, Week 12, Week 24 and Week 52 post-surgery. The score ranging from 0% to 100% indicates the severity of a person's foot issues. A score of 100% indicates worst possible pain, while 0% indicates no pain.

    Time frame: Screening to Week 2, Week 6, Week 12, Week 24 and Week 52 post-surgery.

  4. Functional

    Change in Visual Analog Score (VAS) from Screening to Week 2, Week 6, Week 12, Week 24 and Week 52 post-surgery. 0 no pain and 10 worst pain possible

    Time frame: Screening, Week 2, Week 6, Week 12, Week 24 and Week 52 post-surgery.

  5. Functional

    Change in SF-12 from Screening to Week 2, Week 6, Week 12, Week 24 and Week 52 post-surgery. Where 50 is the average health status for general U.S population. A score above 50 indicates better than average, while a score below 50 suggests below average health.

    Time frame: Screening, Week 2, Week 6, Week 12, Week 24 and Week 52 post-surgery.

07

Study locations

7 of 7 sites recruiting
  • University California Davis
    Sacramento, California 95816, United States
    Recruiting
    • Eric Giza, MD · Principal investigator
  • Steadman Philippon Research Institute
    Vail, Colorado 81657, United States
    Recruiting
  • Hughston Foundation Inc
    Columbus, Georgia 31909, United States
    Recruiting
  • OrthoCarolina Research Institute, Inc
    Charlotte, North Carolina 28207, United States
    Recruiting
  • Reconstructive Orthopaedic Associates II dba Rothman Orthopaedic Institute
    Philadelphia, Pennsylvania 19107, United States
    Recruiting
  • Integrity Orthopedics and Sports Medicine
    Chattanooga, Tennessee 37404, United States
    Recruiting
    • Principal Investigator, Jesse Doty, MD · Contact
  • Centers for Advanced Orthopaedics
    Falls Church, Virginia 22042, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Oct 2028, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2025
First posted
Nov 10, 2025
StartActual
Nov 25, 2025
Primary completionEst.
Oct 2028
CompletionEst.
Dec 2028
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07225751
Lead sponsor
Kuros Biosurgery AG
Responsible party
Sponsor
First posted
Nov 10, 2025
Start date
Nov 25, 2025
Primary completion
Oct 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Sep 1, 2026

Study contacts

Cesar Silva, MD
Contact
cesar.silva@kurosbio.com
9702156793

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion